Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in pneumonia: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS probably leads to lower moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in severe exacerbations: low‐risk population compared with LABA (high certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS leads to higher pneumonia: low‐risk population compared with LABA (high certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA (low certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in pneumonia: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA probably leads to lower pneumonia: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · Adults with acute asthma
1 finding from 1 review
Intervention not reported
Health‐related quality of life (respiratory specific) St George's Respiratory Questionnaire (SGRQ; total score) Scale from 0‐100 Lower value post intervention is favourable, indicating improvement in health‐related quality of life · people with stable COPD
1 finding from 1 review
Intervention not reported
Breathlessness ‐ all trials Lower score indicates improvement in breathlessness · patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
1 finding from 1 review
Intervention not reported
Breathlessness ‐ subgroup analysis ‐ studies using short‐burst oxygen Lower score indicates improvement in breathlessness · patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
1 finding from 1 review
Intervention not reported
Breathlessness ‐ subgroup analysis ‐ studies not using short‐burst oxygen Lower score indicates improvement in breathlessness · patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
1 finding from 1 review
Intervention not reported
Breathlessness ‐ subgroup analysis ‐ studies measuring during exercise test Lower score indicates improvement in breathlessness · patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
1 finding from 1 review
Intervention not reported
Breathlessness ‐ subgroup analysis ‐ studies not measuring during exercise test Lower score indicates improvement in breathlessness · patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · people with asthma
Vilanterol and fluticasone furoate showed no clear difference in peak expiratory flow compared with placebo (moderate certainty).
1 finding from 1 review
MD 33.3
2012 participants
Moderate
Intervention not reported
Asthma control (ACQ) Scale 0 to 6; lower is better12 months · adults or children with asthma
1 finding from 1 review